Cell2Cure ApS will provide patients, physicians and health care systems around the word with easy to use “off-the-shelf” highly effective and safe stem cell products developed from adipose tissue derived mesenchymal stromal cells (ASCs) from healthy donors, for the treatment of patients with a wide range of diseases.
Cell2Cure develops ASC products in clinically relevant formulations, applied in promising new therapeutic concepts for several diseases. Pre-clinical studies and clinical phase I and II trials have demonstrated, that the ASC products can be used as a regenerative therapy in diseases with a high degree of inflammation, tissue ischemia and fibrosis. The products have proven safety and promising efficacy in more than 300 patients with heart failure, left bundle branch block in the heart, reduced tear production in Sjögren’s syndrome, radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients, and in lung transplantation patients. Cell2Cure has a clinical pipeline in a wide range of new disease indications, where inflammation and tissue regeneration plays a role.
Cell2Cure ApS is a clinical-stage biotherapeutic company using allogeneic adipose tissue derived mesenchymal stromal cells for clinical cellular therapies. It is a spinout company from Cardiology Stem Cell Centre, Rigshospitalet…
Research, Technology & IP
Cell2Cure are providing stem cell solutions for a market where there is a recognized unmet need for a source of high quality stem cells.
Cell2Cure interact actively with hospitals, doctors, research groups and the regulatory agencies to advance clinical programs towards registration and marketing.
INVESTOR & PARTNER
We are looking for financial partners / investors that will join us in the development of our company.
Cell2Cure are seeking partners to exploit the full potential of the C2C-ASC technology, partners that may carry out pre-clinical investigations, clinical studies or introduce / test C2C-ASC in existing stem cell development programs.
If you have a serious interest in exploring partnering opportunities – you may contact Cell2Cure.
Our vision is to develop ‘off-the-shelf’ therapeutic cell products with our advanced scalable production technology without animal products, that can be an effective new regenerative and immunosuppressive therapy in a variety of different chronic disease patient populations without present effective curative treatment options.
Cell2Cure ApS is a clinical-stage biotherapeutic company using allogeneic adipose tissue derived mesenchymal stromal cells for clinical cellular therapies. It is a spinout company from Cardiology Stem Cell Centre, Rigshospitalet Copenhagen University Hospital, Denmark.
The developed ‘off-the-shelf’ C2C-ASC cell product is being evaluated as a regenerative therapy in a range of advanced-stage diseases with involvement of blood circulatory disturbance, fibrosis and scar development, and inflammatory and immunological activity including cardiovascular diseases and heart failure.
The management team behind Cell2Cure covers all relevant areas of expertise. In the team we have expertise in clinical development, heart diseases, quality , regulatory affairs and the manufacture of biologicals, specifically live cell-based pharmaceuticals.
Professor Jens Kastrup MD, DMSc, FESC
CEO and clinical director
Annette Ekblond M.Sc., Ph.D.
Director of R&D, GMP and regulatory affairs
Mandana Haack-Sørensen M.Sc., Ph.D.
Director of manufacturing
Martin Roland Jensen M.Sc. Ph.D.
SME Instrument grant
This project has received funding from the European Union’s SME Instrument, Horizon 2020 research and innovation programme under grant agreement No [H2020-SMEINST-868284_PRO-SCT]
Grand Solution Grant
Cell2Cure, as part of the consortium Clinical Stem cell Innovation and production Center, CSIC, receives funding from Innovation Fund Denmark.